Disseminated herpes zoster infection 16 months after last intake of alemtuzumab: potential long-term adverse effects.
Clin Exp Dermatol
; 46(3): 550-552, 2021 Apr.
Article
in En
| MEDLINE
| ID: mdl-32810347
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Immunocompromised Host
/
Multiple Sclerosis, Relapsing-Remitting
/
Alemtuzumab
/
Herpes Zoster
/
Immunosuppressive Agents
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Adult
/
Humans
/
Male
Language:
En
Journal:
Clin Exp Dermatol
Year:
2021
Document type:
Article
Affiliation country:
Germany
Publication country:
ENGLAND
/
ESCOCIA
/
GB
/
GREAT BRITAIN
/
INGLATERRA
/
REINO UNIDO
/
SCOTLAND
/
UK
/
UNITED KINGDOM